Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26169963.
- Also identified by DOI 10.1158/1078-0432.CCR-15-1211 and PMC identifier 4720502.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M) mutation, yet acquired resistance to these agents emerges. Additional mutations in EGFR can confer resistance that, depending on their genomic context, could determine new drug sensitivities of the cancer cells.
Medical subject headings
- Acrylamides
- Alleles
- Antineoplastic Agents
- Drug Resistance, Neoplasm
- ErbB Receptors
- Mutation
- Protein Kinase Inhibitors
- Pyrimidines